Skip to main content

Table 2 Distribution of the studied cases according to different parameters in cases group (n = 43)

From: Potential use of microRNA-590 biomarkers verses plasma calcitonin gene-related peptide for diagnosis of migraine

 

n. (%)

Migraine type

 

 Chronic

25 (58.1%)

 Episodic

18 (41.9%)

Chronic illness

13 (30.2%)

 Type of illness (n = 13)

 

  Diabetes

2 (15.4%)

  Hypertension

3 (23.1%)

  Cholesterol

2 (15.4%)

  Thyroid

3 (23.1%)

  Polyarthralgia

1 (7.7%)

  Osteo Malacia

1 (7.7%)

  Facial palsy

1 (7.7%)

Drugs

 

 Abortive

29 (67.4%)

 Prophylactic

26 (60.5%)

 Topiramate

21 (48.8%)

 Tryptizol

10 (23.3%)

 Ketolac

8 (18.6%)

 Oral contraceptives

4 (9.3%)

 Triptan

18 (41.9%)

 Inderal

3 (7%)

 Compliance

20 (46.5%)

 Status migrainosis

11 (25.6%)

Duration of migraine (years)

 

 Mean ± SD

8.81 ± 7.81

 Median (Min.–Max.)

6 (1–30)

Number of headache /months

 

 Mean ± SD

15.86 ± 10.54

 Median (Min.–Max.)

15 (1–30)

Severity of migraine

 

 Mean ± SD

8.26 ± 1.33

 Median (Min.–Max.)

8 (5–10)